-
Uncategorized7 days ago
Celiac Disease Study Reveals Fiber Benefits Depend on Gut Microbiome
The autoimmune disorder celiac disease results in mucosal inflammation and injury of the small intestine, driven by dietary gluten, resulting in a wide range of varied...
-
Uncategorized7 days agoSTAT+: Baby KJ scientists hit road bump in quest to scale custom gene editor
The scientists behind treating Baby KJ say they’ve hit a stumbling block in their efforts to create more custom gene editing treatments for children with rare...
-
Uncategorized7 days ago
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease...
-
Uncategorized7 days ago
Iterum initiates wind-down after failure to offload antibiotic with sluggish sales
Irish antibiotic specialist Iterum Therapeutics has started winding down its operations, citing limited cash amid the expensive commercialization of its only approved product, Orlynvah.
-
Uncategorized7 days agoSTAT+: Pharmalittle: We’re reading about pharma delaying launches in Europe, Lilly and Biogen deals, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where...
-
Uncategorized1 week ago
Avo raises $10M to help doctors with workflow
Avo, a startup that uses patients’ health records to help doctors handle paperwork and make decisions, has raised $10 million, Endpoints News learned exclusively. When a...
-
Uncategorized1 week agoA new survey examines mental health outcomes of gender euphoria
Good morning. Reporters get countless email pitches every day. Just yesterday, I got one that mentioned Hannah Montana in the subject line. But the pitch that...
-
Uncategorized1 week ago
Merck joins forces with Infinimmune to find therapeutic antibodies
Merck is tasking a 10-person biotech to hunt for new human antibody candidates. The drug giant will ship up to $838 million to the startup, called...
-
Uncategorized1 week agoMerck strikes deal with antibody discovery startup
In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets. Read More
-
Uncategorized1 week ago
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases
Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
